Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.

Autor: Boothby AB; Department of Hematology, University of Washington, Seattle, WA., Tanner MK; Internal Medicine Residency, University of Washington, Seattle, WA., Alswied A; Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD., Youngs D; Bloodworks Northwest, Seattle, WA., Bribiesca Rodriguez J; School of Medicine, University of Washington, Seattle, WA., Bikkani T; Medical Student Volunteer Program, University of Washington, Seattle, WA., Cha N; Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD., Gernsheimer T; Division of Hematology/Oncology, University of Washington, Seattle, WA.; Division of Hematology/Oncology, Fred Hutchinson Cancer Center, Seattle, WA., Gimferrer I; Bloodworks Northwest, Seattle, WA., Hess JR; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA., Sokol-Hessner L; Medicine Center for Scholarship in Patient Care Quality and Safety, University of Washington, Seattle, WA., Marivada S; Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa, FL., Nash MG; Division of Statistical Support, Institute of Translational Health Science, University of Washington, Seattle, WA., Flegel WA; Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD., Vassallo RR; Vitalant Medical Affairs, Scottsdale, AZ., Stroncek DF; Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD., Tsang HC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA., Panch SR; Division of Hematology/Oncology, University of Washington, Seattle, WA.; Division of Hematology/Oncology, Fred Hutchinson Cancer Center, Seattle, WA.

Publikováno v: Blood advances [Blood Adv] 2024 Sep 10; Vol. 8 (17), pp. 4689-4699.

Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.

Autor: Jain S; Division of Hematology, Oncology, and Cell Therapy, Rush University Medical Center, Chicago, IL, USA., Gernsheimer T; Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, Seattle, WA, USA., Kolodny S; Sobi, Inc, Durham, NC, USA., Bernheisel C; Sobi, Inc, Durham, NC, USA., Vredenburg M; Sobi, Inc, Durham, NC, USA., Panch SR; Division of Hematology, University of Washington, Seattle, WA, USA.; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Publikováno v: Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2195016.

Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays.

Autor: Ma J; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Shao L; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Fuksenko T; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Liu H; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Shi R; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Dinh A; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Zhang N; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Panch SR; Department of Medicine (Hematology Division), University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, USA., Somerville RP; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Stroncek DF; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA., Jin P; Center for Cellular Engineering, Department of Transfusion Medicine and Center for Cellular Engineering, National Instates of Health Clinical Center, Bethesda, Maryland, USA. Electronic address: PJin@mail.cc.nih.gov.

Publikováno v: Cytotherapy [Cytotherapy] 2023 Jun; Vol. 25 (6), pp. 598-604. Date of Electronic Publication: 2023 Mar 21.

Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.

Autor: Guru Murthy GS; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Logan BR; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Bo-Subait S; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota, USA., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida, USA., Devine S; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota, USA., Farhadfar N; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida, USA., Gowda L; Yale Cancer Center and Yale School of Medicine, New Haven, Connecticut, USA., Hashmi S; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE., Lazarus H; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA., Nathan S; Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Yared JA; Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States., Stefanski HE; CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota, USA., Pulsipher MA; Division of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA., Hsu JW; Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida, USA., Switzer GE; Departments of Medicine, Psychiatry, and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Panch SR; Fred Hutchinson Cancer Center/University of Washington, School of Medicine, Seattle, Washington, USA., Shaw BE; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2023 Apr; Vol. 98 (4), pp. 608-619. Date of Electronic Publication: 2023 Jan 16.

Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia.

Autor: Jiang D; Division of Hematology, University of Washington, Seattle, WA., Panch SR; Division of Hematology, University of Washington, Seattle, WA.; Transfusion Services, Fred Hutchinson Cancer Center, Seattle, WA.

Publikováno v: Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2022 Dec 09; Vol. 2022 (1), pp. 437-441.